Tags

Type your tag names separated by a space and hit enter

One-week therapy for Helicobacter pylori eradication: ranitidine bismuth citrate plus medium-dose clarithromycin and either tinidazole or amoxycillin.
Aliment Pharmacol Ther 1998; 12(6):539-43AP

Abstract

BACKGROUND

One-week ranitidine bismuth citrate (RBC)-based triple regimens may be effective for the eradication of Helicobacter pylori. We evaluated the efficacy of two short-term RBC-based eradicating therapies including RBC plus medium-dose clarithromycin and either tinidazole or amoxycillin.

METHODS

Seventy consecutive patients, who underwent gastroscopy for dyspeptic symptoms and were found to be H. pylori-positive, were randomly subdivided into two groups receiving either RBC 400 mg b.d. plus clarithromycin 250 mg t.d.s. and tinidazole 500 mg b.d. (group RBCCT) or RBC 400 mg b.d. plus clarithromycin 250 mg t.d.s. plus amoxycillin 1 g b.d. (group RBCCA). H. pylori status was evaluated by means of histology and rapid urease test at entry, and by 13C-urea breath test alone 8 weeks after treatment.

RESULTS

Sixty-nine out of 70 enrolled patients completed the study: 35/35 in group RBCCT and 34/35 in group RBCCA. One patient in group RBCCA was lost to follow-up. In group RBCCT, at the end of treatment, 32 of 35 patients were H. pylori-negative (per protocol analysis 91%, intention-to-treat analysis 91%; 95% CI: 77-98%). In group RBCCA, 31 of 34 patients returned H. pylori-negative (per protocol 91%; 95% CI: 76-98%, intention-to-treat 89%; 95% CI: 73-97%). Slight side-effects occurred in 3/35 patients (9%) in group RBCCT and in 3/34 (9%) in group RBCCA.

CONCLUSIONS

One-week regimens consisting of RBC plus clarithromycin and either tinidazole or amoxycillin, combine high eradication rates with modest side-effects. No substantial difference was found between the two treatment regimens tested in this trial.

Authors+Show Affiliations

Department of Internal Medicine, Catholic University SC, Rome, Italy.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

9678813

Citation

Cammarota, G, et al. "One-week Therapy for Helicobacter Pylori Eradication: Ranitidine Bismuth Citrate Plus Medium-dose Clarithromycin and Either Tinidazole or Amoxycillin." Alimentary Pharmacology & Therapeutics, vol. 12, no. 6, 1998, pp. 539-43.
Cammarota G, Cannizzaro O, Tursi A, et al. One-week therapy for Helicobacter pylori eradication: ranitidine bismuth citrate plus medium-dose clarithromycin and either tinidazole or amoxycillin. Aliment Pharmacol Ther. 1998;12(6):539-43.
Cammarota, G., Cannizzaro, O., Tursi, A., Papa, A., Gasbarrini, A., Cuoco, L., ... Gasbarrini, G. (1998). One-week therapy for Helicobacter pylori eradication: ranitidine bismuth citrate plus medium-dose clarithromycin and either tinidazole or amoxycillin. Alimentary Pharmacology & Therapeutics, 12(6), pp. 539-43.
Cammarota G, et al. One-week Therapy for Helicobacter Pylori Eradication: Ranitidine Bismuth Citrate Plus Medium-dose Clarithromycin and Either Tinidazole or Amoxycillin. Aliment Pharmacol Ther. 1998;12(6):539-43. PubMed PMID: 9678813.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - One-week therapy for Helicobacter pylori eradication: ranitidine bismuth citrate plus medium-dose clarithromycin and either tinidazole or amoxycillin. AU - Cammarota,G, AU - Cannizzaro,O, AU - Tursi,A, AU - Papa,A, AU - Gasbarrini,A, AU - Cuoco,L, AU - Cianei,R, AU - Armuzzi,A, AU - Fedeli,P, AU - Fedeli,G, AU - Gasbarrini,G, PY - 1998/7/25/pubmed PY - 1998/7/25/medline PY - 1998/7/25/entrez SP - 539 EP - 43 JF - Alimentary pharmacology & therapeutics JO - Aliment. Pharmacol. Ther. VL - 12 IS - 6 N2 - BACKGROUND: One-week ranitidine bismuth citrate (RBC)-based triple regimens may be effective for the eradication of Helicobacter pylori. We evaluated the efficacy of two short-term RBC-based eradicating therapies including RBC plus medium-dose clarithromycin and either tinidazole or amoxycillin. METHODS: Seventy consecutive patients, who underwent gastroscopy for dyspeptic symptoms and were found to be H. pylori-positive, were randomly subdivided into two groups receiving either RBC 400 mg b.d. plus clarithromycin 250 mg t.d.s. and tinidazole 500 mg b.d. (group RBCCT) or RBC 400 mg b.d. plus clarithromycin 250 mg t.d.s. plus amoxycillin 1 g b.d. (group RBCCA). H. pylori status was evaluated by means of histology and rapid urease test at entry, and by 13C-urea breath test alone 8 weeks after treatment. RESULTS: Sixty-nine out of 70 enrolled patients completed the study: 35/35 in group RBCCT and 34/35 in group RBCCA. One patient in group RBCCA was lost to follow-up. In group RBCCT, at the end of treatment, 32 of 35 patients were H. pylori-negative (per protocol analysis 91%, intention-to-treat analysis 91%; 95% CI: 77-98%). In group RBCCA, 31 of 34 patients returned H. pylori-negative (per protocol 91%; 95% CI: 76-98%, intention-to-treat 89%; 95% CI: 73-97%). Slight side-effects occurred in 3/35 patients (9%) in group RBCCT and in 3/34 (9%) in group RBCCA. CONCLUSIONS: One-week regimens consisting of RBC plus clarithromycin and either tinidazole or amoxycillin, combine high eradication rates with modest side-effects. No substantial difference was found between the two treatment regimens tested in this trial. SN - 0269-2813 UR - https://www.unboundmedicine.com/medline/citation/9678813/One_week_therapy_for_Helicobacter_pylori_eradication:_ranitidine_bismuth_citrate_plus_medium_dose_clarithromycin_and_either_tinidazole_or_amoxycillin_ L2 - https://onlinelibrary.wiley.com/resolve/openurl?genre=article&sid=nlm:pubmed&issn=0269-2813&date=1998&volume=12&issue=6&spage=539 DB - PRIME DP - Unbound Medicine ER -